News
INCY
120.97
-0.60%
-0.73
Incyte won't move ahead with phase 3 trial of ovarian cancer asset
Seeking Alpha · 1d ago
Incyte Discontinues Planned Phase 3 Ovarian Cancer Study
TipRanks · 1d ago
Incyte Has Decided Not To Proceed With The Planned Phase 3 MAESTRA-3 Study Evaluating INCB123667; Company Does Not Expect This Determination To Affect Its Financial Guidance Or Its Previously Disclosed Long-term Outlook
Benzinga · 1d ago
Incyte will not proceed with planned Phase 3 MAESTRA-3 study of INCB123667
TipRanks · 1d ago
Incyte (INCY) Expands Beyond JAKAFI, Is The Stock Still Cheap?
Simply Wall St · 2d ago
Natera announces clinical collaboration with Incyte
TipRanks · 4d ago
Natera Enters Into Clinical Collaboration Agreement With Incyte For New Phase II Study In Colorectal Cancer
Benzinga · 4d ago
Analysts’ Top Healthcare Picks: Pacific Edge Limited (PFGTF), ADC Therapeutics (ADCT)
TipRanks · 4d ago
Weekly Report: what happened at INCY last week (1102-1106)?
Weekly Report · 5d ago
Raised Sales Guidance Could Be A Big Test For Incyte Stock (INCY)
Simply Wall St · 5d ago
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Novavax (NVAX)
TipRanks · 11/06 13:00
Incyte’s Upcoming ASH 2026 Data for ’989 Support Buy Rating; $152 Price Target Unchanged
TipRanks · 11/05 22:47
Incyte Price Target Cut to $150.00/Share From $154.00 by Leerink Partners
Dow Jones · 11/05 21:32
Incyte Is Maintained at Outperform by Leerink Partners
Dow Jones · 11/05 21:32
Leerink Partners Maintains Outperform on Incyte, Lowers Price Target to $150
Benzinga · 11/05 21:20
$1000 Invested In Incyte 20 Years Ago Would Be Worth This Much Today
Benzinga · 11/05 15:34
Leerink Partners Reaffirms Their Buy Rating on Incyte (INCY)
TipRanks · 11/05 14:32
Is Incyte (INCY) Undervalued On Trial Progress And Raised Sales Guidance?
Simply Wall St · 11/05 12:28
Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
Barchart · 11/04 15:06
Incyte To Present New Data On Its 30 Abstracts At American Society Of Hematology Annual Meeting
Benzinga · 11/04 14:08
More
Webull provides a variety of real-time INCY stock news. You can receive the latest news about Incyte Corp through multiple platforms. This information may help you make smarter investment decisions.
About INCY
Incyte Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics. It operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise consists of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. It also includes VGA039, a novel monoclonal antibody in Phase III development for von Willebrand disease (VWD). It manages business activities through the development and commercialization of oncology and dermatology products.